Cellzome’s president and chief executive Tim Edwards has been elected chairman of the BioIndustry Association. Commenting on his election he …
A round-up of recent news from the CRO sector, featuring updates from Cyprotex, INC Research, Laxai Pharma, Asuragen, Jubilant Organosys …

Former Sanofi-Aventis UK chairman and managing director Nigel Brooksby has joined Cheshire, UK-based Prism Ideas as non-executive chairman. The medical …

Abbott’s weight-loss drug Meridia increases the risk of stroke and heart attack in patients with heart disease, according a study …
Genzyme’s chief executive Henri Termeer has said his company could be for sale to Sanofi-Aventis if it offers a ‘fair …
Pfizer has bolstered its presence in rare and orphan diseases with the acquisition of FoldRx, a US drug discovery firm …
Cephalon’s chairman and chief executive Frank Baldino Jr is taking a medical leave of absence with immediate effect. The company …
In a recent conversation with the head of an international group of medical agencies, I was somewhat surprised to hear …

Bayer Healthcare has launched a new disease awareness campaign that uses augmented reality techniques to engage with its target audience. …
French biotech firm Transgene has received positive scientific advice from the EMA for late stage trials of its new lung …
Belgian biopharma company ThromboGenics could have a major product on its hands in the shape of new eye treatment. The …

The European Medicines Agency has launched a review of GlaxoSmithKline’s influenza vaccine Pandemrix. The European Commission asked the EMA to …
The iPhone and its new, larger cousin the iPad, have captured the hearts of many technology lovers, and have ushered …
Mark Roseman has joined clinical research organisation Kendle as senior vice president and chief marketing officer. He has more than …
CRF Health’s Greg Jewett and Medpace’s Alita Hassan debate the merits of a strategic or a full service contract research …

Roche is reportedly set to cut thousands of pharma jobs to reduce costs and boost profitability following a series of …
Oxford, UK-based PharmaVentures has appointed Paul Phull as a senior director to its corporate advisory business. He joins the company …
Novartis’ Tasigna has received its first European approval as a first-line treatment after Swiss authorities green-lighted the blood cancer drug …
Sanofi-Aventis has gone public with its $18.5 billion offer for Genzyme after the US biotech’s board unanimously rejected the bid …
Swiss contract manufacturer and fine chemicals firm Lonza has expanded its biologics production capacity with the purchase of US firm …